The DOI matches its Crossref record; 184 of the 185 references it cites were found in a registry or an index.
Apoptosis and necroptosis in the liver: a matter of life and death
Open accessAbstract
Cell death represents a basic biological paradigm that governs outcomes and long-term sequelae in almost every hepatic disease condition. Acute liver failure is characterized by massive loss of parenchymal cells but is usually followed by restitution ad integrum. By contrast, cell death in chronic liver diseases often occurs at a lesser extent but leads to long-term alterations in organ architecture and function, contributing to chronic hepatocyte turnover, the recruitment of immune cells and activation of hepatic stellate cells. These chronic cell death responses contribute to the development of liver fibrosis, cirrhosis and cancer. It has become evident that, besides apoptosis, necroptosis is a highly relevant form of programmed cell death in the liver. Differential activation of specific forms of programmed cell death might not only affect outcomes in liver diseases but also offer novel opportunities for therapeutic intervention. Here, we summarize the underlying molecular mechanisms and open questions about disease-specific activation and roles of programmed cell death forms, their contribution to response signatures and their detection. We focus on the role of apoptosis and necroptosis in acute liver injury, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and liver cancer, and possible translations into clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A key feature of MASH is hepatocyte apoptosis, which correlates with the clinically most important feature of the disease, liver fibrosis (6, 7).”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current study amends this fibrocentric concept by demonstrating fibrosis-independent roles for HSCs through RSPO3, regulating critical parameters that affect CLD progression and outcomes, including metabolic hepatocyte functions, liver regeneration and hepatocyte death2,49,50.”
From Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hepatocyte apoptosis is a key feature of metabolic dysfunction–associated steatohepatitis (MASH)”
From Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction–associated steatohepatitis (2025) · cites this paper as [6]
In the citing paper
“In NASH, hepatocytes undergo apoptosis, necroptosis or pyroptosis (a newly described caspase 1-dependent apoptosis observed in NASH),33 thereby initiating inflammation in several ways.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [33]
In the citing paper
“Whilst this process has anti-inflammatory potential, as it removes intracellular content which could otherwise act as DAMPs, efferocytosis also triggers macrophages to release transforming growth factor (TGF)β.”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [33]
In the citing paper
“This signalling pathway positively and negatively modulates inflammation in a number of ways, including via the activation of HSCs, a key source of scar-producing myofibroblasts.33,41”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Apoptosis and Molecular Targeting Therapy in Cancer
Hassan, M. K., Watari, H., Abu-Almaaty, A. H., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,155
RetractedFerroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695
Mizgerd, J. P., Kubo, H., Kutkoski, G. J., Bhagwan, S. D., Scharffetter-Kochanek, K., Beaudet, A. L., & Doerschuk, C. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1357 · Cited by 7,332
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732
Apoptosis, oncosis, and necrosis. An overview of cell death.
Majno, G., & Joris, I. (1995) · PubMed · Cited by 3,328
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Cited by
Sorted by citations
Microbiota in health and diseases
Hou, K., Wu, Z.-X., Chen, X.-Y., Wang, J.-Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00974-4 · Cited by 3,171
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
The multifaceted role of ferroptosis in liver disease
Chen, J., Li, X., Ge, C., Min, J., & Wang, F. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00941-0 · Cited by 683
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Self-citationImmune cell-mediated features of non-alcoholic steatohepatitis
Huby, T., & Gautier, E. L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00639-3 · Cited by 573
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Self-citationHow does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H., & Moshage, H. J. (2021) · Hepatology International · doi:10.1007/s12072-020-10121-2 · Cited by 465
ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis
He, F., Zhang, P., Liu, J., Wang, R., Kaufman, R. J., Yaden, B. C., & Karin, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.016 · Cited by 408
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity
Hirao, H., Nakamura, K., & Kupiec‐Weglinski, J. W. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00549-8 · Cited by 384
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis
Filliol, A., Saito, Y., Nair, A., Dapito, D. H., Yu, L.-X., Ravichandra, A., Bhattacharjee, S., Affo, S., Fujiwara, N., Su, H., et al. (2022) · Nature · doi:10.1038/s41586-022-05289-6 · Cited by 349
Self-citationYamada, N., Karasawa, T., Kimura, H. J., Watanabe, S., Komada, T., Kamata, R., Sampilvanjil, A., Ito, J., Nakagawa, K., Kuwata, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2334-2 · Cited by 342
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Fujii, H., Kawada, N., & Japan Study Group of NAFLD (JSG-NAFLD) (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113863 · Cited by 308
Yamada, N., Karasawa, T., Wakiya, T., Sadatomo, A., Ito, H., Kamata, R., Watanabe, S., Komada, T., Kimura, H. J., Sanada, Y., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15773 · Cited by 280
Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression
Caligiuri, A., Gentilini, A., Pastore, M., Gitto, S., & Marra, F. (2021) · Cells · doi:10.3390/cells10102759 · Cited by 283
Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
Cai, B., Dongiovanni, P., Corey, K. E., Wang, X., Shmarakov, I. O., Zheng, Z., Kasikara, C., Davra, V., Meroni, M., Chung, R. T., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.013 · Cited by 266
Self-citationLytic cell death in metabolic liver disease
Gautheron, J., Gores, G. J., & Rodrigues, C. M. P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.001 · Cited by 225
“Necroptosis is probably the best-understood form of regulated necrosis, since it shares multiple molecular components with the extrinsic apoptotic pathway and can act as a fail-safe mechanism to ensure cell death progression when apoptosis is abnormally inhibited, which may also be relevant in pathological conditions…”
BackgroundTillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 214
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
Ohtani, N., & Kawada, N. (2019) · Hepatology Communications · doi:10.1002/hep4.1331 · Cited by 187
Wu, X., Poulsen, K. L., Sanz‐García, C., Huang, E., McMullen, M. R., Roychowdhury, S., Dasarathy, S., & Nagy, L. E. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.023 · Cited by 183
Pathophysiological mechanisms underlying MAFLD
Kuchay, M. S., Choudhary, N. S., & Mishra, S. K. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.026 · Cited by 188
Mitochondrial DNA in liver inflammation and oxidative stress
Zhang, X., Wu, X., Hu, Q., Wu, J., Wang, G., Hong, Z., & Ren, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.020 · Cited by 170
Tacke, F., & Weiskirchen, R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4354 · Cited by 154
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
Koh, E. H., Yoon, J. E., Ko, M. S., Leem, J., Yun, J.-Y., Hong, C. H., Cho, Y. K., Lee, S. E., Jang, J. E., Baek, J. Y., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-322509 · Cited by 156
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., Huang, N., Ge, C., Wang, G., Gonzalez, F. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14138-6 · Cited by 154
Wu, L., Mo, W., Feng, J., Li, J., Yu, Q., Li, S., Zhang, J., Chen, K., Ji, J., Dai, W., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15099 · Cited by 154
PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF
Li, J., Liang, X., Jiang, J., Yang, L., Xin, J., Shi, D., Lu, Y., Li, ., Ren, K., Hassan, H. M., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-323395 · Cited by 139
Mesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury
Hu, C., Zhao, L., Zhang, L., Bao, Q., & Li, L. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01895-1 · Cited by 130
Dong, J., Viswanathan, S., Adami, E., Singh, B. K., Chothani, S. P., Ng, B., Lim, W., Zhou, J., Tripathi, M., Ko, N. S. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20303-z · Cited by 125
The role of bile acids in cholestatic liver injury
Cai, S., & Boyer, J. L. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-5110 · Cited by 129
Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment
Yang, X., Li, Q., Liu, W., Zong, C., Wei, L., Shi, Y., & Han, Z. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00983-5 · Cited by 120
Understanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
Self-citationRoles of Ceramides in Non-Alcoholic Fatty Liver Disease
Hajduch, É., Lachkar, F., Ferré, P., & Foufelle, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040792 · Cited by 116
Schwabe, R. F., & Brenner, D. A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01068-6 · Cited by 112
Self-citationHepatic stellate cells control liver zonation, size and functions via R-spondin 3
Sugimoto, A., Saito, Y., Wang, G., Sun, Q., Yin, C., Lee, K. H., Geng, Y., Rajbhandari, P., Hernandez, C., Steffani, M., et al. (2025) · Nature · doi:10.1038/s41586-025-08677-w · Cited by 133
Self-citationRole of Oxidative Stress in Liver Disorders
Conde de la Rosa, L., Goicoechea, L., Torres, S., Garcia-Ruiz, C., & Fernandez-Checa, J. C. (2022) · Livers · doi:10.3390/livers2040023 · Cited by 107
Tao, L., Yi, Y., Chen, Y., Zhang, H., Jie, J., Zhang, W., Xu, Q., Li, Y., Ørning, P., Lien, E., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00668-w · Cited by 105
Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy
Wei, J., Zhao, Y., Liang, H., Du, W., & Wang, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.026 · Cited by 108
Mederacke, I., Filliol, A., Affo, S., Nair, A., Hernandez, C., Sun, Q., Hamberger, F., Brundu, F., Chen, Y., Ravichandra, A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abe5795 · Cited by 103
Self-citationThe role of necroptosis in disease and treatment
Liu, X., Xie, X., Ren, Y., Shao, Z., Zhang, N., Li, L., Ding, X., & Zhang, L. (2021) · MedComm · doi:10.1002/mco2.108 · Cited by 110
Programmed cell death in alcohol-associated liver disease
Miyata, T., & Nagy, L. E. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0142 · Cited by 101
Jang, J. Y., Im, E., & Kim, N. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213689 · Cited by 100
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Long, X., Liu, M., Nan, Y., Chen, Q., Xiao, Z., Xiang, Y., Ying, X., Sun, J., Huang, Q., & Ai, K. (2024) · Advanced Materials · doi:10.1002/adma.202308239 · Cited by 97
Radiotherapy modulates tumor cell fate decisions: a review
Chen, H., Han, Z., Luo, Q., Wang, Y., Li, Q., Zhou, L., & Zuo, H.-D. (2022) · Radiation Oncology · doi:10.1186/s13014-022-02171-7 · Cited by 101
Feng, D., Xiang, X., Guan, Y., Guillot, A., Lu, H., Chang, C., He, Y., Wang, H., Pan, H., Ju, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166954 · Cited by 93
Jiao, L., Li, M., Shao, Y., Zhang, Y., Gong, M., Yang, X., Wang, Y., Tan, Z., Sun, L., Xuan, L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2136-6 · Cited by 93
Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
Kuchay, M. S., Choudhary, N. S., & Ramos‐Molina, B. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00951.2024 · Cited by 104
O-GlcNAc transferase suppresses necroptosis and liver fibrosis
Zhang, B., Li, M., Yin, R., Liu, Y., Yang, Y., Mitchell-Richards, K., Nam, J. H., Li, R., Wang, L., Iwakiri, Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127709 · Cited by 95
Zhou, X., Chen, Y., Wang, F., Wu, H., Zhang, Y., Liu, J., Cai, Y., Huang, S., He, N., Hu, Z., et al. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109273 · Cited by 97
Zhao, J., Xie, C., Wang, K., Takahashi, S., Krausz, K. W., Lu, D., Wang, Q., Luo, Y., Gong, X., Mu, X., et al. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.08.007 · Cited by 88
Widjaja, A. A., Dong, J., Adami, E., Viswanathan, S., Ng, B., Pakkiri, L. S., Chothani, S. P., Singh, B. K., Lim, W., Zhou, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba8146 · Cited by 82
Shi, H., Wang, X., Li, F., Gerlach, B. D., Yurdagul, A., Moore, M. P., Zeldin, S., Zhang, H., Cai, B., Zheng, Z., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abp8309 · Cited by 85
Zhao, Z., Xin, F., Zhou, D., Xue, Y., Liu, X., Yang, R., Pan, Q., & Fan, J. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i20.2450 · Cited by 85
New drugs for NAFLD: lessons from basic models to the clinic
Reimer, K. C., Wree, A., Roderburg, C., & Tacke, F. (2019) · Hepatology International · doi:10.1007/s12072-019-10001-4 · Cited by 84
Rusyn, I., Arzuaga, X., Cattley, R. C., Corton, J. C., Ferguson, S., Godoy, P., Guyton, K. Z., Kaplowitz, N., Khetani, S. R., Roberts, R. A., et al. (2021) · Hepatology · doi:10.1002/hep.31999 · Cited by 83
MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease
Fang, Z., Dou, G., & Wang, L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59588 · Cited by 83
Donné, R., Saroul-Aïnama, M., Cordier, P., Hammoutène, A., Kaboré, C., Stadler, M., Nemazanyy, I., Galy–Fauroux, I., Herrag, M., Riedl, T., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.06.003 · Cited by 85
Fouassier, L., Marzioni, M., Afonso, M. B., Dooley, S., Gaston, K., Giannelli, G., Rodrigues, C. M. P., Lozano, E., Mancarella, S., Segatto, O., et al. (2019) · Liver International · doi:10.1111/liv.14102 · Cited by 79
Aly, H. A. A., & Eid, B. G. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0149 · Cited by 78
Aizawa, S., Brar, G., & Tsukamoto, H. (2019) · Gut and Liver · doi:10.5009/gnl18486 · Cited by 80
Zhou, R., Ying, J., Qiu, X., Yu, L., Yue, Y., Liu, Q., Shi, J., Li, X., Qu, Y., & Mu, D. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002010 · Cited by 78
Chen, W., Wang, X., Zhao, B., Zhang, R., Xie, Z., He, Y., Chen, A., Xie, X., Yao, K., Zhong, M., et al. (2019) · Nanoscale · doi:10.1039/c9nr03114f · Cited by 75
Park, J.-M., Rah, S., An, H. S., Lee, J. Y., Roh, G. S., Ryter, S. W., Park, J. W., Yang, C. H., Surh, Y., Kim, U., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155516 · Cited by 76
Bai, L., Kong, M., Duan, Z., Liu, S., Zheng, S., & Chen, Y. (2021) · Cell Death & Disease · doi:10.1038/s41419-020-03378-w · Cited by 73
Guo, R., Jia, X., Ding, Z., Wang, G., Jiang, M., Li, B., Chen, S., Xia, B., Zhang, Q., Liu, J., et al. (2022) · Theranostics · doi:10.7150/thno.71400 · Cited by 69
Liu, M., Lu, J., Hu, J., Chen, Y., Deng, X., Wang, J., Zhang, S., Guo, J., Li, W., & Guan, S. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.133719 · Cited by 70
Mitochondrial Mechanisms of Necroptosis in Liver Diseases
Xue, C., Gu, X., Li, G., Bao, Z., & Li, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010066 · Cited by 70
Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury
Liu, M., Huang, Q., Zhu, Y., Chen, L., Li, Y., Gong, Z., & Ai, K. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100215 · Cited by 70
Preston, S., Stutz, M. D., Allison, C. C., Nachbur, U., Gouil, Q. A., Tran, B. M., Duvivier, V., Arandjelovic, P., Cooney, J. P., Mackiewicz, L., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.040 · Cited by 68
Han, X., Zhang, J., Liu, J., Wang, H., Du, F., Zeng, X., & Guo, C. (2022) · APOPTOSIS · doi:10.1007/s10495-022-01785-2 · Cited by 70
Targeting cell death in NAFLD: mechanisms and targeted therapies
Xu, H., Wan, S., An, Y., Wu, Q., Xing, Y.-H., Deng, C.-H., Zhang, P., Long, Y., Xu, B.-T., & Jiang, Z. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02168-z · Cited by 72
Wirtz, T. H., Saal, A., Bergmann, I., Fischer, P., Heinrichs, D., Brandt, E. F., Koenen, M. T., Djudjaj, S., Schneider, K. M., Boor, P., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15622 · Cited by 66
Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives
Lin, L., Wanxin, H., Guo, Y., Zheng, Q., Zefeng, L., Danyang, W., & Huaqin, L. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02121-0 · Cited by 75
Zhao, J., Hu, Y., & Peng, J. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00254-z · Cited by 68
Lee, Y., Wang, J. J., Luu, M., Noureddin, M., Nissen, N. N., Patel, T. C., Roberts, L. R., Singal, A. G., Gores, G. J., & Yang, J. D. (2021) · Hepatology · doi:10.1002/hep.32007 · Cited by 65
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Lambrecht, J., van Grunsven, L. A., & Tacke, F. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774553 · Cited by 64
Infection-Associated Thymic Atrophy
Luo, M., Xu, L., Qian, Z.-Y., & Sun, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652538 · Cited by 70
Zhao, T., Mao, L., Yu, Z., Hui, Y., Feng, H., Wang, X., Lin, L., Fan, X., Chen, X., Wang, B., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107308 · Cited by 63
Inaba, Y., Hashiuchi, E., Watanabe, H., Kimura, K., Oshima, Y., Tsuchiya, K., Murai, S., Takahashi, C., Matsumoto, M., Kitajima, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35804-w · Cited by 65
Mitochondrial Mechanisms of Apoptosis and Necroptosis in Liver Diseases
Chu, Q., Gu, X., Zheng, Q., Wang, J., & Zhu, H. (2021) · Analytical Cellular Pathology · doi:10.1155/2021/8900122 · Cited by 62
Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities
García‐Pras, E., Fernández‐Iglesias, A., Gracia‐Sancho, J., & Pérez‐del‐Pulgar, S. (2021) · Cancers · doi:10.3390/cancers14010048 · Cited by 62
Evoking Ferroptosis by Synergistic Enhancement of a Cyclopentadienyl Iridium‐Betulin Immune Agonist
Lv, M., Zheng, Y., Wu, J., Shen, Z., Guo, B., Hu, G., Huang, Y., Zhao, J., Qian, Y., Su, Z. G., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202312897 · Cited by 59
Differences of Key Proteins between Apoptosis and Necroptosis
Park, M. Y., Ha, S. E., Vetrivel, P., Kim, H. H., Bhosale, P. B., Abusaliya, A., & Kim, G. S. (2021) · BioMed Research International · doi:10.1155/2021/3420168 · Cited by 58
Wang, X., Sommerfeld, M. R., Jahn‐Hofmann, K., Cai, B., Filliol, A., Remotti, H. E., Schwabe, R. F., Kannt, A., & Tabas, I. (2019) · Hepatology Communications · doi:10.1002/hep4.1405 · Cited by 56
Self-citationLiu, W., Shao, T., Tian, L., Ren, Z., Gao, L., Tang, Z., Fang, Z., Yuan, P., Liu, C., Li, J., et al. (2022) · Food & Function · doi:10.1039/d2fo03384d · Cited by 59
Yang, M., Wang, J., Xiao, W., & Fan, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1410668 · Cited by 61
Barangi, S., Mehri, S., Moosavi, Z. B., Hayes, A. W., Reiter, R. J., Cardinali, D. P., & Karimi, G. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.110556 · Cited by 55
Tsuchiya, Y., Seki, T., Kobayashi, K., Komazawa‐Sakon, S., Shichino, S., Nishina, T., Fukuhara, K., Ikejima, K., Nagai, H., Igarashi, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42058-z · Cited by 57
Gu, L., Zhu, Y., Lee, M., Nguyen, A., Ryujin, N. T., Huang, J. Y., Pandit, S. K., Chamseddine, S., Xiao, L., Mohamed, Y. I., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300706120 · Cited by 54
Zhao, Q., Chen, D., Chen, H., Wang, Y., Shi, W. L., Lu, Y., Ren, Y.-Z., Wu, Y., Pang, Y., Deng, H. X., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000868 · Cited by 54
PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway
Han, Z., Liu, D., Chen, L., He, Y., Tian, X., Qi, L., Chen, L., Luo, Y., Chen, Z., Hu, X., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03837-y · Cited by 55
Ye, Q., Zhou, Y., Zhao, C., Xu, L., & Jian, P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.677810 · Cited by 52
Chen, J., Zhang, R., Tao, C., Huang, X., Chen, Z., Li, X., Zhou, J., Zeng, Q., Zhao, B., Yuan, M., et al. (2020) · Nanotoxicology · doi:10.1080/17435390.2020.1759727 · Cited by 52
Acute-on-chronic liver failure (ACLF) in 2022: have novel treatment paradigms already arrived?
Abbas, N., Rajoriya, N., Elsharkawy, A. M., & Chauhan, A. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2097070 · Cited by 56
Targeting regulated chondrocyte death in osteoarthritis therapy
Zhu, R., Wang, Y., Ouyang, Z., Hao, W., Zhou, F., Lin, Y., Cheng, Y., Zhou, R., & Hu, W. M. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115707 · Cited by 52
CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis
Lei, Z., Yu, J., Wu, Y. Z., Shen, J., Lin, S., Xue, W., Mao, C., Tang, R., Sun, H., Qi, X., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.025 · Cited by 51
Activated aggregation‐induced emission therapeutics agents for triggering regulated cell death
Zhao, Y., Yu, L., Zhang, L., Liu, H., Zhou, Y. M., & Kim, J. S. (2024) · Aggregate · doi:10.1002/agt2.503 · Cited by 52
Gungor, M. Z., Uysal, M., & Şentürk, Ş. (2022) · Cancers · doi:10.3390/cancers14040940 · Cited by 53
Metadata
- Authors
- Schwabe, R. F., & Luedde, T.
- Affiliations
- Columbia University Irving Medical Center (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Schwabe, Robert F.
- Luedde, Tom
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2018-09-24
- Volume
- 15
- Issue
- 12
- Pages
- 738-752
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- PMC
- PMC6490680
- OpenAlex
- W2890337997
- Cited by
- 582
- References
- 185
- Citations by year
- 2026: 51 · 2025: 82 · 2024: 93 · 2023: 91 · 2022: 94 · 2021: 78 · 2020: 59 · 2019: 33
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (U01AA021912)
- National Cancer Institute (R01CA190844, R01CA200597)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK116620)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- apoptosis, necroptosis, programmed cell death, liver injury, acute liver failure, chronic liver disease, liver fibrosis, liver cirrhosis, liver cancer, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic stellate cells, hepatocyte turnover, cell death detection
- MeSH terms
- Animals, Humans, Liver, Liver Diseases, Necrosis, Cell Death, Apoptosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
